<ion-view title="Acerca de ICapp" id="presentacion">

    <div class="bar bar-subheader cal-4">
        <h2 class="title negro">Bibliografía</h2>
    </div>

    <ion-content padding="true" class="has-header">
        <div class="spacer" style="width: 300px; height: 60px;"></div>

        <div style="padding: 20px;" class="textos bibliografia">
            <ul>
                <li>Girbés Borrás J, Escalada San Martín J, Mata Cases M, Gómez-Peralta F, Artola Menéndez S, Fernández García D, et al. Consenso sobre tratamiento con insulina en la diabetes tipo 2. Endocrinol Diabetes Nutr 2018;65 Suppl S1:1-8. </li>
                <li>American Diabetes Association. Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41(S1). </li>
                <li>Artola S. Actualización del algoritmo de hiperglucemia 2017. Diabetes Práctica 2017;08(02):49-96. </li>
                <li>Artola S, Mata M, Ezkurra P. Consenso para la insulinización en diabetes mellitus tipo 2 de la RedGDPS. Diabetes Práctica 2017;08(Supl Extr 4):1-24.</li>
                <li>Davies MJ, D'Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Management+of+hyperglycaemia+in+type+2+diabetes%2C+2018.+A+consensus+report+by+the+American+Diabetes+Association+(ADA)+and+the+European+Association+for+the+Study+of+Diabetes+(EASD)" title="Diabetologia.">Diabetologia</a> 2018;61(12):2461-98. </li>
                <li>Deacon CF. A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials. Diabetes Obes Metab 2018;20(Suppl 1):34-46. </li>
                <li>Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2015;373:232-42. </li>
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Jabbour%20SA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30082326">Jabbour SA</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Fr%C3%ADas%20JP%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30082326">Frías JP</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Hardy%20E%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30082326">Hardy E</a>, Ahmed A, Wang H, Öhman P, et al. Safety and Efficacy of Exenatide Once Weekly Plus Dapagliflozin Once Daily Versus Exenatide or Dapagliflozin Alone in Patients With Type 2 Diabetes Inadequately Controlled With Metformin Monotherapy: 52-Week Results of the DURATION-8 Randomized Controlled Trial. <a href="https://www.ncbi.nlm.nih.gov/pubmed/30082326" title="Diabetes care.">Diabetes Care</a> 2018;41(10):2136-46. </li>
                <li>Ludvik B, Frías JP, Tinahones FJ, Wainstein J, Jiang H, Robertson KE, et al. Dulaglutide as add on therapy to SGLT2 inhibitors in patients with inadequately controlled type 2 diabetes (AWARD-10): a 24-week, randomised, double-blind, placebo-controlled trial. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Dulaglutide+as+add-on+therapy+to+SGLT2+inhibitors+in+patients+with+inadequately+controlled+type+2+diabetes+(AWARD-10)%3A+a+24-week%2C+randomised%2C+double-blind%2C+placebo-controlled+trial" title="The lancet. Diabetes &amp; endocrinology.">Lancet Diabetes Endocrinol</a> 2018;6(5):370-81. </li>
                <li>Marso SP Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2016;375:311-22.</li>
                <li>Marso SP, McGuire DK, Zinman B, Poulter NR, Emerson SS, Pieber TR, et al. Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. N Engl J Med 2017;377:723-32. </li>
                <li>Miravet S. Grandes estudios que han marcado la evidencia en el manejo de la diabetes mellitus tipo 2: estudios de seguridad cardiovascular. Diabetes Práctica 2017;08(01):47-8. </li>
                <li>Navarro J. Eficacia y seguridad cardiovascular del control glucémico en personas con diabetes. Diabetes Práctica 2018;09(Supl Extr 1):1-24. </li>
                <li>Neal B, Perkovic V, Mahaffey K, de Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes. N Engl J Med 2017;377:644-57. </li>
                <li>Rosenstock J, Cheng A, Ritzel R, Bosnyak Z, Devisme C, Cali AMG, et al. More Similarities Than Differences Testing Insulin Glargine 300 Units/mL Versus Insulin Degludec 100 Units/mL in Insulin-Naive Type 2 Diabetes: The Randomized Head-to-Head BRIGHT Trial. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=The+BRIGHT+Randomized+Study+glargina" title="Diabetes care.">Diabetes Care</a> 2018;41(10):2147-54.</li>
                <li>Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N,<strong> </strong>et al.<strong> </strong>Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes<strong> </strong>and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial.<strong> </strong>JAMA 2019;321(1):69-79.</li>
                <li>Saigí I, Pérez A. Hiperglucemia inducida por glucocorticoides. Semin Fund Esp Reumatol 2011;12(3):83-90. </li>
                <li>Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 2013;369:1317-26. </li>
                <li>Tejedor A, Bravo A. El riñón, modulador de la respuesta endocrina. Diabetes Práctica 2018;09(03):81-120. </li>
                <li>White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 2013;369:1327-35. </li>
                <li>Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. N Engl J Med 2019;380:347-57.</li>
                <li><a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Zelniker%20TA%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30424892">Zelniker TA</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Wiviott%20SD%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30424892">Wiviott SD</a>, <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=Raz%20I%5BAuthor%5D&amp;cauthor=true&amp;cauthor_uid=30424892">Raz I</a>. SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <a href="https://www.ncbi.nlm.nih.gov/pubmed/?term=SGLT2+Inhibitors+for+Primary+and+Secondary+Prevention+of+Cardiovascular+and+Renal+Outcomes+in+Type+2+Diabetes%3A+A+Systematic+Review+and+Meta-Analysis+of+Cardiovascular+Outcome+Trials.+Lancet+2018" title="Lancet (London, England).">Lancet</a> 2019;393(10166):31-9. </li>
                <li>Zinman B, Wanner C, Lachin J, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. N Engl J Med 2015;373:2117-28. </li>
            </ul>
        </div>

        <div class="spacer" style="width: 300px; height: 20px;"></div>
    </ion-content>
</ion-view>